Viola Meehan
Vermögen: 563 966 $ am 30.09.2026
Vermögen: 563 966 $ am 30.09.2026
Ms. Viola Meehan is on the Board of Directors at Cue Biopharma, Inc. Ms. Meehan was previously employed as a Chief Financial Officer by Vanqua Bio, Inc. and a Vice President by AbbVie, Inc. She received her undergraduate degree from The Wharton School of the University of Pennsylvania and an MBA from The University of Chicago.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 09.07.2026 | 21’800 ( 0.3% ) | 563 966 $ | 30.09.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| CUE BIOPHARMA, INC. | Direktor/Vorstandsmitglied | 30.05.2026 |
| Unternehmen | Position | Ende |
|---|---|---|
Vanqua Bio, Inc.
Vanqua Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as biotechnology company that focused on developing novel therapies for Parkinson's disease | Finanzdirektor/CFO | 01.01.2023 |
| ABBVIE INC. | Corporate Officer/Principal | 01.11.2019 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 5 |
|---|---|
AbbVie, Inc.
AbbVie, Inc. Pharmaceuticals: MajorHealth Technology Engages in the research and development, manufacturing, commercialization & sale of immunology medicines and therapies | Health Technology |
The University of Chicago
The University of Chicago Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Wharton School of the University of Pennsylvania
The Wharton School of the University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cue Biopharma, Inc.
Cue Biopharma, Inc. BiotechnologyHealth Technology Develops biopharmaceuticals | Health Technology |
Vanqua Bio, Inc.
Vanqua Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as biotechnology company that focused on developing novel therapies for Parkinson's disease | Commercial Services |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen